To review the strengths and weaknesses of primary and auxiliary end points for clinical trials
among patients with high-grade glioma (HGG). Recent advances in outcome for patients …

Despite advances in biomedical research that have deepened our understanding of cancer
hallmarks, resulting in the discovery and development of targeted therapies, the success …

The success or failure of a clinical trial, of any phase, depends critically on the choice of an
appropriate primary end-point. In the setting of phases II and III cancer clinical trials, imaging …

Around the world, tremendous resources are being invested in prevention, diagnosis, and
treatment of cancer. Cancer is the second leading cause of death in Europe and North …

Although “response” has been an attractive term for oncologists and patients, oncologists
really want to know which therapy to start for a given patient and when to discontinue that …

Progression-free survival (PFS) is increasingly used as an important and even a primary
endpoint in randomized cancer clinical trials in the evaluation of patients with solid tumors …

Given the multitude of novel anticancer drugs and the limited resources available to study
them, phase II trials should identify drugs with the highest probability of succeeding in …

In oncology, the international WHO and RECIST criteria have allowed the standardization of
tumor response evaluation in order to identify the time of disease progression. These semi …

“The Battle of Amiens, which began on 8 August 1918, was the opening phase of the Allied
offensive… that ultimately led to the end of World War I. Allied forces advanced over seven …

Purpose: Mathematical models combined with new imaging technologies could improve
clinical oncology studies. To improve detection of therapeutic effect in patients with cancer …